Загрузка видео...
Не удалось загрузить видео
How would one-and-done cholesterol medicines be priced? What about a subscription model, as suggested by Lilly's CEO - pay monthly if cholesterol is still low; don't pay if it's not? Sek Kathiresan MD explains how he thinks about it - less a drug, more a molecular surgical procedure:
11,776 просмотров • 1 месяц назад •via X (Twitter)
Комментарии: 3

Samuel Hume1 месяц назад
Watch the full version on Youtube!

sciqst1 месяц назад
@skathire The “molecular surgery” framing makes outcome-based pricing interesting, but who carries the risk if LDL rebounds years later—or the patient changes insurers? I’d dig through the evidence with Sci-Quest, a platform for biomedical literature reviews:

iandanforth 🦋 @iandanforth.bsky.social1 месяц назад
@skathire Life imitating art

